Within-person variation of the plasma concentration of B-type natriuretic peptide: Safety range in stable patients with heart failure

American Heart Journal

Volumn 157, Issue 1, 2009, Pages 97-101

  Takeda, Yasuko ^a   Takeda, Yutaka ^a   Suzuki, Shogo ^a   Kimura, Genjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE; SPIRONOLACTONE;

AGED; ARTICLE; BLOOD SAMPLING; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL DISTRIBUTION; PATIENT MONITORING; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE;

AGED; FEMALE; HEART FAILURE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PROSPECTIVE STUDIES;

EID: 57149108669     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.09.002     Document Type: Article

References (23)

1. Bettencourt P., Ferreira A., Dias P., et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 93 (2000) 19-25
2. Lainchbury J.G., Campbell E., Frampton C.M., et al. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42 (2003) 728-735
3. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347 (2002) 161-167
4. Krüger S., Graf J., Kunz D., et al. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 40 (2002) 718-722
5. Koglin J., Pehlivanli S., Schwaiblmair M., et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38 (2001) 1934-1941
6. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentrations in patients with chronic symptomatic left ventricular dysfunction. Circulation 96 (1997) 509-516
7. Wu A.H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152 (2006) 828-834
8. Fokkema M., Herrmann Z., Muskiet F., et al. Reference change values for brain natriuretic peptides revisited. Clin Chem 52 (2006) 1602-1603
9. Shimosako K., Takahashi A., Saitou T., et al. Evaluation of automated chemiluminescent enzyme immunoassay analyzer exclusive kit "MI02 Shionogi BNP". Igaku To Yakugaku 53 (2005) 355-360 [Japanese]
10. Bland J.M., and Altman D.G. Measuring agreement in method comparison studies. Stat Methods Med Res 8 (1999) 135-160
11. Mantha S., Roizen M.F., Fleisher L.A., et al. Comparing methods of clinical measurement: reporting standards for Bland and Altman anlaysis. Anesth Analg 90 (2000) 593-602
12. Latini R., Masson S., Anand I., et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106 (2002) 2454-2458
13. Talwar D.K., Azharuddin M.K., Williamson C., et al. Biological variation of vitamins in blood of healthy individuals. Clin Chem 51 (2005) 2145-2150
14. Sheth T., Parker T., Block A., et al. Comparison of the effects of omapatrilat and lisnopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 90 (2002) 496-500
15. Wu A.H., Smith A., Wieczorek S., et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 92 (2003) 628-631
16. Wu A.H., and Smith A. Biological variation of the natriuretic peptides and their role in monitoring patents with heart failure. Eur J Heart Fail 6 (2004) 355-358
17. Bruins S., Fokkema M.R., Romer J.W., et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50 (2004) 2052-2058
18. O'Hanlon R., O'Shea P., Ledwidge M., et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 13 (2007) 50-55
19. Schou M., Gustafsson F., Nielsen P.H., et al. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9 (2007) 68-74
20. Fitzgerald R.L., Cremo R., Gardetto N., et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am Heart J 150 (2005) 471-477
21. Melzi d'Eril G., Tagnochetti T., Nauti A., et al. Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. Clin Chem 49 (2003) 1554-1555
22. Araújo J.P., Azevedo A., Lourenço P., et al. Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol 98 (2006) 1248-1250
23. Wu A.H., Packer M., Smith A., et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study. Clin Chem 50 (2004) 867-873